A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy

Completed · Phase 3

Conditions studied: Colonoscopy

In brief

The objective of this study is to compare the safety and efficacy of BLI4700 bowel preparation to an FDA-approved bowel preparation as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.

Key facts

Study ID

NCT03404401

Run by

Braintree Laboratories

People needed

620

Starts

2018-01-11

Expected to finish

2018-07-10

Last updated by the study team

2021-09-08

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
• 18 to 85 years of age (inclusive)
• If female, and of child-bearing potential, is using an acceptable form of birth control
• Negative serum pregnancy test at screening, if applicable
• In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

You may not qualify if…

• Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.
• Subjects with ongoing severe, acute inflammatory bowel disease
• Subjects who had previous significant gastrointestinal surgeries.
• Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
• Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days. NSAID use for occasional pain is not exclusionary.
• Subjects with uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 100 mmHg).
• Subjects taking antibiotics within 7 days of colonoscopy.
• Subjects with severe renal insufficiency (GFR < 30 mL/min/1.73m2).
• Subjects with known severe hepatic insufficiency (Child Pugh C)
• Subjects with cardiac insufficiency (NYHA Functional Classifications 3 or 4).
• Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.
• Subjects undergoing insulin therapy for any indication.
• Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
• Subjects undergoing colonoscopy for foreign body removal and/or decompression.
• Subjects who are pregnant or lactating, or intending to become pregnant during the study.
• Subjects of childbearing potential who refuse a pregnancy test.
• Subjects allergic to any preparation component.
• Subjects using drugs of abuse, including abused prescription medications.
• Subjects who are withdrawing from alcohol or benzodiazepines.
• Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
• Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

Where it is running

• Braintree Research Site 212 — Mobile, Alabama, United States
• Braintree Research Site 204 — Tucson, Arizona, United States
• Braintree Research Site 209 — Anaheim, California, United States
• Braintree Research Site 219 — Chula Vista, California, United States
• Braintree Research Site 206 — Los Angeles, California, United States
• Braintree Research Site 220 — San Diego, California, United States
• Braintree Research Site 221 — Inverness, Florida, United States
• Braintree Research Site 222 — Jacksonville, Florida, United States
• Braintree Research Site 201 — Palm Harbor, Florida, United States
• Braintree Research Site 224 — Atlanta, Georgia, United States
• Braintree Research Site 215 — Decatur, Georgia, United States
• Braintree Research Site 223 — Lake Charles, Louisiana, United States
• Braintree Research Site 211 — Monroe, Louisiana, United States
• Braintree Research Site 207 — Hagerstown, Maryland, United States
• Braintree Research Site 218 — Flowood, Mississippi, United States
• Braintree Research Site 210 — Great Neck, New York, United States
• Braintree Research Site 214 — Cincinnati, Ohio, United States
• Braintree Research Site 213 — Portland, Oregon, United States
• Braintree Research Site 216 — Columbia, South Carolina, United States
• Braintree Research Site 202 — Franklin, Tennessee, United States
• Braintree Research Site 203 — Jackson, Tennessee, United States
• Braintree Research Site 217 — Ogden, Utah, United States
• Braintree Research Site 208 — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.